Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GUSB pseudogene 13 (GUSBP13) is classified as a processed pseudogene, meaning it originated from the retrotransposition of the mRNA transcript of the parental GUSB gene and is inserted at a different genomic locus[5][2]. Pseudogenes like GUSBP13 typically do not code for a functional protein due to the absence of regulatory elements or mutations in the coding sequence[2]. There are multiple pseudogenes related to the human GUSB locus, reflecting a history of retrotranspositional events[1][5]. Pseudogenes, in general, may sometimes participate in gene regulation (for instance, by acting as competing endogenous RNAs in some contexts), but no such function has been specifically ascribed to GUSBP13 in current databases or studies[2][5]. GUSB pseudogene 13 (GUSBP13) is a processed pseudogene, not a protein-coding gene, receptor, enzyme, or therapeutic target. It is correct as a gene symbol and full name and does not have known roles in disease, therapeutic targeting, or biomarker development[5][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GUSB pseudogene 13 (GUSBP13).